Luye Pharmaceutical Buprenorphine Transdermal Patch was approved for research in China

China News Network, February 27, Luye Pharmaceutical recently announced that it has been approved by the China Food and Drug Administration (CFDA) to launch a research and development project of buprenorphine transdermal patch in China. This is the first transdermal patch development project introduced into China since the completion of Luye Pharmaceutical's acquisition of Europe's leading transdermal drug release business at the end of November 2016, showing Luye Pharma's international strategic intention and speed of action of "global resources, China growth".

Developed by Luye pharma ag (Luye Pharma ag), a subsidiary of Luye Pharmaceuticals ( Luye Pharma AG Germany), buprenorphine transdermal patches have been marketed in countries such as the UK, Germany and Spain for severe pain with moderate to severe cancer pain and non-opioid analgesics that are ineffective. Transdermal patch forms are sustainable, stable-release agents that are more convenient and safe to use than injectable and oral formulations. The anesthesia analgesic drug market has high policy barriers and sales barriers, and there is currently only one imported buprenorphine transdermal patch on the market in China, and there are no domestic products. The company also plans to register the product in countries such as the United States, Japan and South Korea.

As analgesic treatments gain more and more clinical attention in China, the market will also have greater potential for development. According to IMS market data, the sales of anesthesia analgesics in 2016 were 5.8 billion yuan, with a compound growth rate of 27.9% from 2012 to 2016 and 30% in 2016, with a good market prospect.

The approval of the project introduced this time is less than 3 months after the completion of international mergers and acquisitions, reflecting the integration ability and speed of Luye Pharmaceutical's business after mergers and acquisitions. With the help of Luye Pharmaceutical Germany's advanced technology platform and R&D expertise in the field of transdermal patches, the company will also introduce more transdermal patch products in the field of central nervous system and other fields to the Chinese market in the future, expand the product line in the domestic market, and provide more choices for clinical practice.